New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-burden follicular lymphoma in need of treatmentAll six patients responded positively to the combination ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback